Cart
sales@molnova.com
Alismol
CAS No. 87827-55-2
Alismol( —— )
Catalog No. M31088 CAS No. 87827-55-2
Alismol has antihypertensive action, it decreases cardiac output, heart rate and left ventricular pressure, but it increases coronary flow, it has been used for the prevention of anginal attacks.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 414 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAlismol
-
NoteResearch use only, not for human use.
-
Brief DescriptionAlismol has antihypertensive action, it decreases cardiac output, heart rate and left ventricular pressure, but it increases coronary flow, it has been used for the prevention of anginal attacks.
-
DescriptionAlismol has antihypertensive action, it decreases cardiac output, heart rate and left ventricular pressure, but it increases coronary flow, it has been used for the prevention of anginal attacks.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number87827-55-2
-
Formula Weight220.4
-
Molecular FormulaC15H24O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Mepacrine
Mepacrine (Erion) is an acridine derivative formerly widely used as an antimalarial. It is used in cell biological experiments as an inhibitor of phospholipase A2.
-
Mepyramine
Mepyramine is a histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies both parenterally and locally.
-
TGFβ1-IN-2
TGFβ1-IN-2, a derivative of diarylacylhydrazones, effectively inhibits fibroblast activation and proliferation and holds potential for idiopathic pulmonary fibrosis (IPF) research .
